Evidence map›Paper›PMID 34464505›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2022

The allograft injury marker CXCL9 determines prognosis of anti-HLA antibodies after lung transplantation.

Michael Y Shino, Qiuheng Zhang, Ning Li, Ariss Derhovanessian, Allison Ramsey, Rajan Saggar, Ian N Britton, Olawale O Amubieya, Shahrzad M Lari, Michelle Hickey and 9 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Michael Y ShinoDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID 0000-0001-9261-1404
Qiuheng ZhangDepartment of Immunogenetics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID 0000-0003-1439-6491
Ning LiDepartment of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Ariss DerhovanessianDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Allison RamseyDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Rajan SaggarDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Ian N BrittonDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Olawale O AmubieyaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Shahrzad M LariDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Michelle HickeyDepartment of Immunogenetics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Elaine F ReedDepartment of Immunogenetics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID 0000-0002-3524-545X
Paul W NobleDepartment of Medicine, Cedars Sinai Medical Center, Los Angeles, California, USA.
Barry R StrippDepartment of Medicine, Cedars Sinai Medical Center, Los Angeles, California, USA.
Gregory A FishbeinDepartment of Pathology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID 0000-0002-3632-5654
Joseph P LynchDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Abbas ArdehaliDivision of Cardiothoracic Surgery, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
David M SayahDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
S Sam WeigtDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID 0000-0001-5351-8936
John A BelperioDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.ORCID 0000-0003-2379-5486
University of California, Los Angeles · USCedars-Sinai Medical Center · US

Funding

The Lung Transplant Clinical Trials Network (LT-CTN)U01AI113315 · NIAID · DUKE UNIVERSITY · PI PALMER, SCOTT M · 2014 to 2018
$12.9M
Non-invasive surveillance of the lung allograft post transplantationK23HL138256 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHINO, YUSAKU MICHAEL · 2017 to 2021
$902k
NHLBI NIH HHS 5U01AI113315-02NHLBI NIH HHS K23 HL138256NIAID NIH HHS U01 AI113315
6 · The paper itself

Abstract

Despite the common detection of non-donor specific anti-HLA antibodies (non-DSAs) after lung transplantation, their clinical significance remains unclear. In this retrospective single-center cohort study of 325 lung transplant recipients, we evaluated the association between donor-specific HLA antibodies (DSAs) and non-DSAs with subsequent CLAD development. DSAs were detected in 30% of recipients and were associated with increased CLAD risk, with higher HRs for both de novo and high MFI (>5000) DSAs. Non-DSAs were detected in 56% of recipients, and 85% of DSA positive tests had concurrent non-DSAs. In general, non-DSAs did not increase CLAD risk in multivariable models accounting for DSAs. However, non-DSAs in conjunction with high BAL CXCL9 levels were associated with increased CLAD risk. Multivariable proportional hazards models demonstrate the importance of the HLA antibody-CXCL9 interaction: CLAD risk increases when HLA antibodies (both DSAs and non-DSAs) are detected in conjunction with high CXCL9. Conversely, CLAD risk is not increased when HLA antibodies are detected with low CXCL9. This study supports the potential utility of BAL CXCL9 measurement as a biomarker to risk stratify HLA antibodies for future CLAD. The ability to discriminate between high versus low-risk HLA antibodies may improve management by allowing for guided treatment decisions.

Indexed as

HLA AntigensLung TransplantationAllograftsBiomarkersChemokine CXCL9Cohort StudiesGraft RejectionGraft SurvivalHumansIsoantibodiesPrognosisRetrospective StudiesTissue DonorsBiomarkersChemokine CXCL9CXCL9 protein, humanHLA AntigensIsoantibodiesalloantibodybiomarkerbronchoalveolar lavage (BAL)cytokine receptorscytokinesdysfunctionimmunobiologylung (allograft) functionlung transplantation / pulmonologytranslational research / science

Identifiers

PMID34464505
PMCPMC10826889
OpenAlexW3197803798

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.